Treatment of degenerated surgical aortic bioprostheses with an intra annular self-expanding transcatheter heart valve: a real-world experience

View at publisher Summarise with VIRAT
Authors: Enrico Criscione, Luca Testa, M Guerrini, Riccardo Gorla, Michele Morosato, Marco Taurian, Antonio Popolo Rubbio, Antonio Sisinni, Marta Barletta, N Brambilla, Francesco Bedogni
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Introduction In the treatment of aortic native valve stenosis, the PORTICO self-expanding transcatheter heart valve (THV) showed similar hemodynamic performance to the Evolut platform. On the other hand, being intra-annular, it is not frequently used in the setting of valve-in-valve (VIV) for a degenerated surgical aortic bioprosthesis. As a consequence, very limited data are available. This study sought to evaluate the procedural and mid-term outcomes of aortic ViV procedures using the Portico THV. Methods we included 117 consecutive patients with a degenerated surgical aortic valve bioprosthesis undergoing VIV with the Portico THV between January 2016 and December 2024 in a high-volume center. VARC-3 definitions were applied. Results The majority of the patients (59, 51%) had a stented bioprosthesis with externally mounted pericardial leaflets. The primary failure mode was stenosis (56, 50%), followed by regurgitation (29, 25%) and mixed etiology (28, 25%). In 82% of the cases, there was a small surgical valve (size ≤ 23 mm). Median time to surgical valve failure was 9 years (IQR 7-12). In 87 cases (74.4%) a 23-mm Portico THV was used. Procedural success was achieved in 98.3% of patients. Device success was 63.2%, primarily limited by residual mean gradient ≥ 20 mmHg (33, 28.7%) and moderate-or-worse paravalvular leak (9, 7.8%). Prosthesis–patient mismatch (PPM) was severe in 10 patients (10.8%): a surgical valve size ≤ 21 mm was an independent predictor of severe PPM at multivariable analysis. At 1-year follow-up: the composite of all-cause death, stroke and HF Hospitalization occurred in 22.1%; NYHA functional class at 1-year improved significantly, with 96% of patients in class I-II; most patients showed none or trivial PVL (N= 74, 63.8%; p 0.134), while mean gradient and AVA remained substantially equal to post procedure. Conclusions the Portico THV appears to be a safe and effective option in the context of TAVI-VIV. Itshemodynamic performance appears to be very favorable, despite its intra-annular position.

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Aortic Disease and Treatment Approaches Infective Endocarditis Diagnosis and Management

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Publication date
1 March 2026
Language
EN